文献速递真菌感染

脂质体两性霉素B对比安慰剂预防急性淋巴细胞白血病侵袭性真菌感染的随机研究

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

独立评估的确诊或临床诊断侵袭性真菌感染率在脂质体两性霉素B组为7.9%(18/228),安慰剂组为11.7%(13/111),差异无统计学意义(P=0.24)。研究方案未能显著降低侵袭性真菌感染发生率,且低钾血症和肌酐升高在脂质体两性霉素B组更常见。

要点

  • 脂质体两性霉素B 5 mg/kg每周两次预防未显著降低成人ALL诱导化疗期间侵袭性真菌感染率。
  • 安慰剂组确诊或临床诊断侵袭性真菌感染率为11.7%,高于既往报告水平。
  • 脂质体两性霉素B组低钾血症和肌酐升高显著更常见,耐受性符合预期。

核心结论

  • 研究的脂质体两性霉素B方案对成人ALL缓解诱导化疗期间侵袭性真菌感染无显著预防效果。
  • 安慰剂组侵袭性真菌感染率高于既往报告,值得进一步研究。
  • 最佳抗真菌策略尚需进一步研究确定。

研究设计与样本

  • 双盲多中心3期随机对照研究。
  • 主要终点为确诊或临床诊断侵袭性真菌感染;次要终点包括安全性和耐受性。
  • 共86个中心参与,分布于欧洲和南美洲。
  • 两组缓解诱导期中位时间均为22天。

主要发现

  • 独立评估的确诊或临床诊断侵袭性真菌感染率:脂质体两性霉素B组7.9%(18/228),安慰剂组11.7%(13/111),P=0.24。
  • 可能侵袭性真菌感染率:脂质体两性霉素B组4.8%(11/228),安慰剂组5.4%(6/111),P=0.82。
  • 总死亡率:脂质体两性霉素B组7.2%(17/237),安慰剂组6.8%(8/118),P=1.00。
  • 低钾血症和肌酐升高在脂质体两性霉素B组显著更常见。

临床怎么用

  • 不推荐将本研究所用脂质体两性霉素B方案(5 mg/kg每周两次)常规用于成人ALL缓解诱导化疗期间侵袭性真菌感染预防。
  • 使用脂质体两性霉素B时需监测低钾血症和肾功能。
  • 成人ALL诱导化疗期间的最佳抗真菌预防策略需进一步研究确定。

局限性

  • 原文未报告样本量计算依据、置信区间及具体不良反应发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prevent invasive fungal disease (IFD) in adult patients undergoing remission-induction chemotherapy for newly diagnosed acute lymphoblastic leukaemia (ALL). PATIENTS AND METHODS: In a double-blind multicentre Phase 3 study, patients received prophylactic liposomal amphotericin B (L-AMB) at 5 mg/kg intravenously or placebo twice weekly in a 2:1 random allocation during remission-induction treatment. The primary endpoint was the development of proven or probable IFD. Secondary endpoints included those focused on the safety and tolerability of prophylactic L-AMB. RESULTS: Three hundred and fifty-five patients from 86 centres in Europe and South America received at least one dose of L-AMB ( n = 237) or placebo ( n = 118). Rates of proven and probable IFD assessed independently were 7.9% (18/228) in the L-AMB group and 11.7% (13/111) in the placebo group ( P = 0.24). Rates of possible IFD were 4.8% (11/228) in the L-AMB and 5.4% (6/111) in the placebo group ( P = 0.82). The remission-induction phase was a median of 22 days for both groups. Overall mortality was similar between the groups: 7.2% (17/237) for L-AMB and 6.8% (8/118) for placebo ( P = 1.00). Hypokalaemia and creatinine increase were significantly more frequent with L-AMB. CONCLUSIONS: The IFD rate among adult patients undergoing remission-induction chemotherapy for newly diagnosed ALL was 11.7% in the placebo group, and was not significantly different in patients receiving L-AMB, suggesting that the L-AMB regimen studied is not effective as prophylaxis against IFD. The IFD rate appears higher than previously reported, warranting further investigation. Tolerability of L-AMB was what might be expected. Further studies are needed to determine the optimal antifungal strategy during remission-induction chemotherapy of ALL.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017. PMID: 28575414. doi:10.1093/jac/dkx133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。